• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: 10 best, 10 worst U.S. stocks in January

    UPDATE: 10 best, 10 worst U.S. stocks in January

  2. 10 best, 10 worst U.S. stocks in January

    10 best, 10 worst U.S. stocks in January

  3. Russian stocks, U.S. banks remain clear winners in Trump trade

    Russian stocks, U.S. banks remain clear winners in Trump trade

  4. Testosterone Replacement Therapy Market: By Therapies & Region - Forecast (2016-2021) - Research and Markets

    Testosterone Replacement Therapy Market: By Therapies & Region - Forecast (2016-2021) - Research and Markets

  5. Prostate Cancer Report 2017 - Newer Antiandrogens & Emerging Therapies Targeting a Watchful Waiting and Resistance Population - Research and Markets

    Prostate Cancer Report 2017 - Newer Antiandrogens & Emerging Therapies Targeting a Watchful Waiting and Resistance Population - Research and Markets

  6. EndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy

    EndoBarrierĀ® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy

  7. UPDATE: What to expect from Johnson & Johnson earnings

    UPDATE: What to expect from Johnson & Johnson earnings

  8. What to expect from Johnson & Johnson earnings

    What to expect from Johnson & Johnson earnings

  9. World Breast Biopsy Market - Opportunities and Forecasts, 2014 - 2022 - Research and Markets

    World Breast Biopsy Market - Opportunities and Forecasts, 2014 - 2022 - Research and Markets

  10. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

12

©2017 Morningstar Advisor. All right reserved.